RE: RE: Newbie QuestionA comment from a reliable source about the study in Italy:
The EUPHAS study was halted because the Toraymyxin group saw such an increased mortality benefit over standard of care it was unethical not to provide the placebo group, who were only receiving standard of care, the potential mortality benefits resulting from the combination of PMX and standard of care. However, two aspects of this comment are incorrect: firstly, Spectral did not perform this study and secondly, this was not a study that utilized the EAA™ product.
The potential seems to be outstanding, if SDI can jump through the hoops. I would have thought that there should/could have been a lot more patients that could have used this 'treatment', since the study was completed, especially in the countries that don't have to have "approval", FDA or otherwise. Probably hard to convince other doctors that the treatment is better, despite the results shown.